Although well established in their treatment of certain cancers involving the lung, skin, and genitourinary systems, PD-1/PD-L1 inhibitors have not been shown to provide significant benefits for other cancers, one of them being prostate cancer [72]. This evidence concerns the gene PDCD1 and cancer.